| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aloe vera — a medicinal succulent (Aloe barbadensis Miller) used as a complex botanical mixture whose clinically used preparations typically derive from (i) the inner leaf gel (polysaccharide-rich) and/or (ii) whole-leaf extracts containing anthraquinones. It is best classified as a botanical/natural product mixture (not a single agent). Common abbreviations include AV (Aloe vera). Key bioactives often discussed in oncology-adjacent literature include polysaccharides such as acemannan (immunomodulatory/wound-healing biomaterial profile) and anthraquinones such as aloe-emodin/emodin/aloin (more directly cytotoxic in vitro, but also linked to GI toxicity/carcinogenic hazard signals in certain whole-leaf preparations). Primary mechanisms (ranked):
Bioavailability / PK relevance: Aloe preparations are heterogeneous. High–molecular-weight gel polysaccharides (e.g., acemannan) have limited systemic bioavailability and are most relevant for local mucosal/skin exposure or immune-adjacent effects; anthraquinones are more systemically absorbable but undergo metabolism and are constrained by GI tolerance and safety concerns. “Decolorized/low-anthraquinone” products differ materially from nondecolorized whole-leaf extracts. In-vitro vs systemic exposure relevance: Many reported anticancer effects use crude extracts or isolated anthraquinones at concentrations that may exceed typical achievable systemic levels from oral supplements; supportive-care benefits (skin/mucosa) are more plausibly local exposure–driven. Clinical evidence status: Predominantly preclinical for direct anticancer activity. Human evidence is mainly supportive-care (e.g., radiation dermatitis and oral mucositis), with mixed RCT outcomes and heterogeneous formulations; there is no high-quality evidence establishing Aloe vera as a primary anticancer therapy. Aloe vera Therapeutic properties include: anti-microbial, anti-viral, anti-cancer, anti-oxidant, anti-inflammatory, skin protection, wound healing, and regulation of blood glucose and cholesterol.active constituents, such as aloe-emodin and acemannan. • Aloe vera extracts harbor antioxidant compounds that can scavenge free radicals, protecting cells from oxidative damage—a factor in aging and cancer development. Aloe vera’s blend of bioactive compounds offers a range of biological activities—including anti-inflammatory, antioxidant, immunomodulatory, and wound-healing effects—that have attracted interest for complementary roles in health maintenance and cancer supportive care. While it is not a primary anticancer agent, its potential to mitigate treatment side effects, enhance immune responses, and possibly contribute to chemoprevention makes it a subject of ongoing research. Aloe vera — mechanistic axes relevant to cancer and supportive care
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Source: |
| Type: |
| Glutathione (GSH) is a thiol antioxidant that scavenges reactive oxygen species (ROS), resulting in the formation of oxidized glutathione (GSSG). Decreased amounts of GSH and a decreased GSH/GSSG ratio in tissues are biomarkers of oxidative stress. Glutathione is a powerful antioxidant found in every cell of the body, composed of three amino acids: cysteine, glutamine, and glycine. It plays a crucial role in protecting cells from oxidative stress, detoxifying harmful substances, and supporting the immune system. cancer cells can have elevated levels of glutathione, which may help them survive in the oxidative environment created by the immune response and chemotherapy. This can make cancer cells more resistant to treatment. While glutathione can be obtained from certain foods (like fruits, vegetables, and meats), its absorption from supplements is debated. Some people take N-acetylcysteine (NAC) or other precursors to boost glutathione levels, but the effects on cancer prevention or treatment are still being studied. Depleting glutathione (GSH) to raise reactive oxygen species (ROS) is a strategy that has been explored in cancer research and therapy. Many cancer cells have altered redox states and may rely on GSH to survive. Increasing ROS levels can induce stress in these cells, potentially leading to cell death. Certain drugs and compounds can deplete GSH levels. For example, agents like buthionine sulfoximine (BSO) inhibit the synthesis of GSH, leading to its depletion. Cancer cells tend to exhibit higher levels of intracellular GSH, possibly as an adaptive response to a higher metabolism and thus higher steady-state levels of reactive oxygen species (ROS). "...intracellular glutathione (GSH) exhibits an astounding antioxidant activity in scavenging reactive oxygen species (ROS)..." "Cancer cells have a high level of GSH compared to normal cells." "...cancer cells are affluent with high antioxidant levels, especially with GSH, whose appearance at an elevated concentration of ∼10 mM (10 times less in normal cells) detoxifies the cancer cells." "Therefore, GSH depletion can be assumed to be the key strategy to amplify the oxidative stress in cancer cells, enhancing the destruction of cancer cells by fruitful cancer therapy." The loss of GSH is broadly known to be directly related to the apoptosis progression. |
| 5362- | AV, | Anti-cancer effects of aloe-emodin: a systematic review |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:28 Target#:137 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid